Pages that link to "Q33406904"

The following pages link to Emphasis on the Role of PF4 in the Incidence, Pathophysiology and Treatment of Heparin Induced Thrombocytopenia (Q33406904):

Displaying 12 items.

• Advances in the pathophysiology and treatment of heparin-induced thrombocytopenia (Q33416269) (← links)
• The unique immunological features of heparin-induced thrombocytopenia. (Q33440626) (← links)
• Unfractionated heparin versus low molecular weight heparins for avoiding heparin-induced thrombocytopenia in postoperative patients. (Q33441234) (← links)
• Anti-Platelet Factor 4/Heparin Antibody Formation Occurs Endogenously and at Unexpected High Frequency in Polycythemia Vera. (Q33443580) (← links)
• Evaluation of Immunostimulatory Potential of Branded and US-Generic Enoxaparins in an In Vitro Human Immune System Model (Q35465768) (← links)
• Elevated heparin-induced antibodies are more common in diabetic patients with vascular disease. (Q37615123) (← links)
• Delayed-onset heparin-induced thrombocytopenia complicated by arterial and venous thromboses (Q48286495) (← links)
• STS/SCA/AmSECT Clinical Practice Guidelines: Anticoagulation during Cardiopulmonary Bypass. (Q52646041) (← links)
• Cross-Species Analysis of Glycosaminoglycan Binding Proteins Reveals Some Animal Models Are "More Equal" than Others (Q64057893) (← links)
• Heparin Forms Polymers with Cell-free DNA Which Elongate Under Shear in Flowing Blood (Q91666501) (← links)
• Profiling Heparin-Induced Thrombocytopenia (HIT) Antibodies in Hospitalized Patients With and Without Diabetes (Q93010476) (← links)
• Current Perspectives on Diagnostic Assays and Anti-PF4 Antibodies for the Diagnosis of Heparin-Induced Thrombocytopenia (Q98945581) (← links)